Innovative research aims to improve wound healing and cancer therapy

Freiburg researcher Priscilla Briquez receives ERC Starting Grant for innovative approach to protein engineering

30-Oct-2023 - Jun.-Prof. Dr. Priscilla Briquez, junior professor at the Department of General and Visceral Surgery at the Freiburg University Medical Center and member of the Medical Faculty at the University of Freiburg, has received a European Research Council (ERC) Starting Grant from the European ...

iOmx Therapeutics appoints Dr. Nils Peter Debus as Chief Business Officer

06-Sep-2023 - iOmx Therapeutics AG (iOmx), a clinical stage biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, announced the appointment of Dr. Nils Peter Debus as Chief Business Officer (CBO) to drive the company’s new stage of growth. Dr. Debus is an ...

BioNTech and DualityBio form global strategic partnership

Focus on accelerated development of differentiated antibody-drug conjugates therapeutics for solid tumors

04-Apr-2023 - BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. (DualityBio), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate (“ADC”) therapeutics to treat patients with cancer and autoimmune diseases, announced that the companies have ...

New checkpoint antibody against cancer

BioNTech and OncoC4 announce strategic collaboration

22-Mar-2023 - BioNTech SE and OncoC4, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel biologicals for cancer treatment, announced that they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4’s ...

BioNTech and Ryvu Therapeutics enter partnership

Research collaboration for several small molecule immunotherapy programs

02-Dec-2022 - BioNTech SE and Ryvu Therapeutics S.A., a clinical-stage company developing oncology therapeutics announced that the companies have entered into a multi-target research collaboration for several small molecule immunotherapy programs as well as an exclusive license agreement for Ryvu’s STING ...

CatalYm Closes EUR 50 Million Series C Financing

Start-up develops a "new anti-cancer immunotherapeutic drug with the potential to transform the immuno-oncology landscape"

24-Nov-2022 - CatalYm announced the close of a EUR50 million (USD49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, ...

iOmx Therapeutics raises EUR 65 million in Series B round

The new funds will be used to advance iOmx´ lead programs IMT-07 and IMT-18, both addressing novel immune checkpoint targets in oncology

08-Oct-2021 - iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, announced the closing of a Series B round totaling EUR 65 million. The financing was co-led by Athos Service GmbH – the Strüngmann family office – and MIG ...

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Office

06-May-2021 - CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced the appointment of Dr. Phil L’Huillier as Chief Executive Officer (CEO), effective May 17, 2021. Dr. Phil L’Huillier brings over two decades of experience in executive leadership positions in the ...

€12M Series A Financing to Develop Novel Immuno-Virotherapies Against Cancer

17-Oct-2019 - Abalos Therapeutics announced a EUR 12 million Series A financing round establishing its operations and leadership. The Company’s objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating ...

Sanofi Invests EUR 80m in BioNTech

07-Jan-2019 - BioNTech AG announced that it has extended its research collaboration with Sanofi initiated in late 2015 and Sanofi is investing* EUR 80 million (approximately USD 91.5 million) in equity in BioNTech. Simultaneously BioNTech has entered into an agreement with Sanofi to co-develop the first cancer ...